0000000000244071

AUTHOR

Dan Atar

showing 3 related works from this author

Diagnostic Accuracy and Usability of the ECG247 Smart Heart Sensor Compared to Conventional Holter Technology

2021

Background. Heart rhythm disorders, especially atrial fibrillation (AF), are increasing global health challenges. Conventional diagnostic tools for assessment of rhythm disorders suffer from limited availability, limited test duration time, and usability challenges. There is also a need for out-of-hospital investigation of arrhythmias. Therefore, the Norwegian ECG247 Smart Heart Sensor has been developed to simplify the assessment of heart rhythm disorders. The current study aimed to evaluate the diagnostic accuracy and usability of the ECG247 Smart Heart Sensor compared to conventional Holter monitors. Methods. Parallel tests with ECG247 Smart Heart Sensor and a Holter monitor were perform…

MaleMedicine (General)TechnologyHolter monitormedicine.medical_specialtyRhythm analysisArticle SubjectHeart rhythm disordersBiomedical EngineeringHealth InformaticsDiagnostic accuracyDiagnostic toolsElectrocardiographyR5-920Heart RateAtrial FibrillationMedical technologymedicineHumansR855-855.5medicine.diagnostic_testbusiness.industryAtrial fibrillationUsabilityMiddle Agedmedicine.diseaseTest durationEmergency medicineElectrocardiography AmbulatoryFemaleSurgerybusinessResearch ArticleBiotechnologyJournal of Healthcare Engineering
researchProduct

Clinical review: impact of statin substitution policies on patient outcomes.

2009

Background. The increasing awareness of cost issues in health care has led to the increasing use of policy-driven substitution of branded for generic medications, particularly relative to statin treatment for cardiovascular diseases. While there are potential short-term health care savings, the consequences for primary care are under-researched. Our objective was to review data on intensive statin therapy and generic substitution in patients at high cardiovascular risk. Results. Current treatment guidelines for the prevention of cardiovascular disease are consistent in their recommendations regarding statin therapy and treatment targets. Clinical trials demonstrate that to reduce cardiovasc…

medicine.medical_specialtyStatinCost effectivenessmedicine.drug_classDiseasePlaceboReimbursement MechanismsRisk FactorsHealth caremedicineDrugs GenericHumanscardiovascular diseasesIntensive care medicinebusiness.industryPublic healthHealth Policynutritional and metabolic diseasesGeneral MedicineClinical trialEuropeCardiovascular DiseasesPractice Guidelines as TopicPhysical therapyObservational studylipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsbusiness
researchProduct

Prognostic Value of Microvascular Obstruction and Infarct Size, as Measured by CMR in STEMI Patients

2014

The aim of this study was to evaluate the value of microvascular obstruction (MO) and infarct size as a percentage of left ventricular mass (15%LV), as measured by contrast-enhanced cardiac magnetic resonance, in predicting major cardiovascular adverse events (MACE) at 2 years in patients with ST-segment elevation myocardial infarction reperfused by primary percutaneous coronary intervention. Individual data from 1,025 patients were entered into the pooled analysis. MO was associated with the occurrence of MACE, defined as a composite of cardiac death, congestive heart failure, and myocardial re-infarction (adjusted hazard ratio: 3.74; 95% confidence interval: 2.21 to 6.34). IS% LV >= 25% w…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentmicrovascular obstructionHeart VentriclesMyocardial Infarction[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineRisk Assessmentcardiac magnetic resonance[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicinePercutaneous Coronary InterventionPredictive Value of TestsRecurrenceRisk FactorsInternal medicineCoronary CirculationMedicineinfarct sizeHumansRadiology Nuclear Medicine and imagingMyocardial infarctioncardiovascular diseasesAdverse effectComputingMilieux_MISCELLANEOUSAgedHeart Failurebusiness.industryMicrocirculationMyocardiumHazard ratioPercutaneous coronary interventionMiddle Agedmedicine.diseaseMagnetic Resonance ImagingConfidence intervalTreatment OutcomeRadiology Nuclear Medicine and imagingHeart failureNo reflow phenomenonCardiologyNo-Reflow PhenomenonFemaleprognosisCardiology and Cardiovascular MedicinebusinessMaceJACC. Cardiovascular imaging
researchProduct